| Literature DB >> 32630156 |
Tzu-Hsuan Wei1, Ching-Liang Hsieh1,2,3.
Abstract
Acupuncture is clinically used to treat various diseases and exerts positive local and systemic effects in several nervous system diseases. Advanced molecular and clinical studies have continually attempted to decipher the mechanisms underlying these effects of acupuncture. While a growing understanding of the pathophysiology underlying several nervous system diseases shows it to be related to inflammation and impair cell regeneration after ischemic events, the relationship between the therapeutic mechanism of acupuncture and the p38 MAPK signal pathway has yet to be elucidated. This review discusses the latest advancements in the identification of the effect of acupuncture on the p38 signaling pathway in several nervous system diseases. We electronically searched databases including PubMed, Embase, and the Cochrane Library from their inception to April 2020, using the following keywords alone or in various combinations: "acupuncture", "p38 MAPK pathway", "signaling", "stress response", "inflammation", "immune", "pain", "analgesic", "cerebral ischemic injury", "epilepsy", "Alzheimer's disease", "Parkinson's disease", "dementia", "degenerative", and "homeostasis". Manual acupuncture and electroacupuncture confer positive therapeutic effects by regulating proinflammatory cytokines, ion channels, scaffold proteins, and transcription factors including TRPV1/4, Nav, BDNF, and NADMR1; consequently, p38 regulates various phenomena including cell communication, remodeling, regeneration, and gene expression. In this review article, we found the most common acupoints for the relief of nervous system disorders including GV20, GV14, ST36, ST37, and LI4. Acupuncture exhibits dual regulatory functions of activating or inhibiting different p38 MAPK pathways, contributing to an overall improvement of clinical symptoms and function in several nervous system diseases.Entities:
Keywords: acupuncture; nervous system diseases; p38 signaling pathway
Mesh:
Substances:
Year: 2020 PMID: 32630156 PMCID: PMC7370084 DOI: 10.3390/ijms21134693
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Summary of the signal transduction pathways through which acupuncture treats nervous system diseases. Acupuncture is applied on acupoints and results in de qi, evoking the excitation of cell membrane receptors, such as the Tyrosine receptor kinase and TLR/ligand, and subsequently producing signal transduction. AC: adenyl cyclase; Akt: protein kinase B; AMPK: AMP-activated protein kinase; ASK-1: apoptosis signal-regulating kinase 1; Bad: Bcl-2-associated death promoter; Bax: Bcl-2 associated X; Bcl-2: B-cell lymphoma 2; Bcl2-xl: B-cell lymphomaextralarge; cAMP: cyclic adenosine monophosphate; CREB: cAMP response element-binding protein; ERK: extracellular signal-regulated kinase; IP3: inositol triphosphate; JNK: c-Jun N-terminal kinases; Elk-1: erythroblast transformation specific (ETS) like-1 protein; Max: a transcription factor coded by the myc-associated factor X; MEF: myocyte-enhancing factor; MEK: MEK kinase; MEKK: MK kinase kinase; MSK: mitogen- and stress-activated protein kinase; Myc: a group of transcription factors coded by regulator genes and a proto-oncogene called Myc; MyD88: myeloid differentiation primary response 88; TLRs: Toll-like receptors; NF-κB: nuclear factor kappa B; Pax6: a paired-box protein encoded by the master gene Pax-6; PI3K: phosphatidylinositol-4,5-bisphosphate 3-kinase; PKA: protein kinase A; PKC: protein kinase C; ATF: activating transcription factor; AP-1: activator protein; CHOP: C/EBP homologous; Stat1: signal transducer and activator of transcription 1.
Figure 2Three major subfamilies of mitogen-activated protein kinases (MAPKs) include extracellular signal-regulated kinases (ERKs), the c-Jun amino-terminal kinases (JNKs), and the p38 MAPKs. The solid lines ending with arrowheads denote activated proteins, solid lines with blunt ends denote deactivated proteins, and the dotted lines with blunt ends denote partially deactivated proteins.
Members of the p38 mitogen-activated protein kinase (MAPK) subfamily.
| p38 Subfamily | Other Names | Upstream | Location/Function | Dysfunction and Diseases |
|---|---|---|---|---|
| p38α | MAPK14, SAPK2a, CSBP | MKK3, MKK4, MKK6, MKK7 | Ubiquitously expressed at significant levels in most cell types. Involved in the regulation of cell proliferation, differentiation, development, and response to stress [ | Defective placental angiogenesis causing embryo death (mouse), symmetric synchronous cell cleavage (zebrafish), reduction in erythropoietin (Epo) production [ |
| p38β | MAPK 11 | MKK3, MKK4, MKK6 | Ubiquitously expressed; upregulated in the CNS and lungs, downregulated in the healthy heart [ | No phenotype found [ |
| p38γ | MAPK 13, ERK6, SAPK3 1 | MKK3, MKK4, MKK6MKK7 | Myoblast and skeletal muscle./(1) Under stress conditions, they act on scaffold proteins targeting the plasma membrane cytoskeleton at sites of neuromuscular junctions and gap junctions [ | No phenotype found (mouse) [ |
| p38δ | MAPK 12, SAPK4 | MKK3, MKK4, MKK6, MKK7 | Only expressed in the lungs, kidney, testis, spleen, pancreas, and small intestine in humans, rats, and mice, but not in other vertebrates; enriched in endocrine glands [ | No phenotype found [ |
SAPK: stress-activated protein kinase; CNS: central nervous system; mTORC1: mammalian target of rapamycin complex 1 or mechanistic target of rapamycin complex 1; NAFLD: nonalcoholic fatty liver disease.
Figure 3The four p38 MAPK isoforms are p38α, p38β, p38γ, and p38δ. Solid lines denote activated proteins, and dotted lines denote partially activated proteins. MNK: mitogen-activated protein kinase-interacting protein; MSK: mitogen- and stress-activated protein kinase; cPLA2: cytosolic phospholipase A2; ATF2: the activating transcription factor 2; Elk-1: the [erythroblast transformation specific (ETS)] like-1 protein; SAP1: stress-activated protein 1; PSD: postsynaptic density proteins; eEF2: eukaryotic elongation factor 2.
Figure 4The p38 MAPK signaling pathways. Solid lines indicate signaling pathways and the proteins involved in them; dotted lines indicate the regulatory mechanisms reported in several studies, and lines with blunt ends indicate pathways inhibiting or deactivating downstream substrates. LPS: lipopolysaccharide; TGFβ: growth factor beta; TLRs: Toll-like receptors; CD40: cluster of differentiation 40 receptors; GPCRs: G-protein-coupled receptors; elF2a: eukaryotic translation initiation factor 2A; ER: endoplasmic reticulum; NF-κB: nuclear factor kappa B; TAB1: TGF-beta-activated kinase1; TRADD: tumor necrosis factor receptor type 1-associated DEATH domain protein; TRAF: tumor necrosis factor receptor (TNFR)-associated factor; Daxx: death domain-associated protein; RIP: receptor-interacting protein kinases; MyD88: myeloid differentiation primary response 88; PRAK: p38-regulated and -activated kinase; Hsp: heat shock proteins; DLK: dual leucine zipper kinase; MLK: mixed-lineage protein kinase; MEKK: MEKK kinase; MEK: MEK kinase; MKK: MK kinase; MNK: mitogen-activated protein kinase-interacting protein; TAO: thousand and one amino acids; eEF2K: eukaryotic elongation factor 2 kinase; cPLA2, cytosolic phospholipase A2; ATF: activating transcription factor; MSK: mitogen- and stress-activated protein kinase; CREB: cAMP response element–binding protein; AP-1: activator protein 1; MEF: myocyte enhancing factor; CHOP: C/EBP homologous protein, a member of the CCAAT/enhancer-binding proteins; Elk-1: erythroblast transformation specific (ETS) like-1 protein; Stat1: signal transducer and activator of transcription 1; Pax6: a paired-box protein encoded by the master gene Pax-6; Myc: a group of transcription factors coded by a regulator genes and proto-oncogene called Myc; Max: a transcription factor coded by the myc-associated factor X.
Figure 5AMPK-activated-p38α pathways in ischemic heart tissue. Arrow: activated; TAK-1: transforming growth factor-β-activated kinase 1; AMPK: 5’ AMP-activated protein kinase; P: phospho-; AMP: adenosine mono-phosphate; ATP: adenosine tri-phosphate; AMP/ATP: AMP/ATP ratio; ACC1: Acetyl-CoA carboxylase 1; Fas signal pathway, Fas and Fas Ligand (FasL) regulate cell death; HMG-CoA reductase: a rate-controlling enzyme of the mevalonate pathway responsible for cholesterol and other isoprenoid biosynthesis.
Figure 6Schematic of the potential mechanism underlying the electroacupuncture (EA)-mediated analgesic effect. Noxious stimuli including heat or proinflammatory cytokines are transduced by the transient receptor potential vanilloid 1 (TRPV1) into the cells, thus phosphorylating and activating p38, which translocates from the cytosol to the nucleus and promotes transcription by affecting cAMP response element-binding protein (CREB), thus upregulating specific proteins including inflammatory cytokines or inducing apoptosis. These noxious stimuli can also directly activate protein kinase C (PKC). Nociception regulation by TRPV1 and Nav1.7/1.8 receptor stimulation in the peripheral nerves propagates the signal through the ascending pathway and upregulates proinflammatory cytokines including cyclooxygenase-2 (COX-2) and tumor necrosis factor-α (TNFα) in the central nervous system, and the signal is then perceived as “pain”. Chronic pain re-emerges when nociceptive signals cause prolonged stimulation through hippocampal N-methyl-D-aspartate receptor (NMDA) receptors and some other areas of the limbic system, and the signals are transmitted through the descending pathway, stimulating TRPV4 and triggering pain. Endogenic analgesic mechanisms involve the release of opioidergic substances that bind to γ-aminobutyric acidergic (GABAergic) receptors and μ- or δ-opioid receptors that act locally in the central nervous system and inhibit the descending pain pathway. EA exerts therapeutic effects by inhibiting the ascending pain pathway and intracellular p38-mediated inflammatory pathway by stimulating peripheral opioid receptors. Furthermore, EA promotes endogenic analgesic mechanisms, thus exerting immediate local analgesic effects and rescuing CNS-induced chronic pain.
The effect of acupuncture on inflammatory and neuropathic pain.
| Study | Model | Intervention | Acupoints | Evaluation | Result |
|---|---|---|---|---|---|
| Hsu et al., (2014) [ | SD rats | CCI-induced neuropathic pain; EA, 2- and 15-Hz, 20 min | Ipsilateral ST36-ST37 of the affected limb | Behavioral responses to stimuli; expression of TRPV1/4 in the cerebral cortex and lumbar spinal cord | EA relieved neuropathic pain; downregulation of cerebral TRPV4 expression. |
| Jiang et al., (2018) [ | SD rats | CCI-induced neuropathic pain; EA, 2- and 15-Hz, 20 min | Bilateral L4-L6 Hua Tuo Jia Ji (EX-B2) | GABAA, A1R, TRPV1/4, and mGluR3 in the DRG | EA reduced the pain response, upregulating the GABAA receptor in the spinal cord. |
| Huang et al., (2019) [ | SD rats | CCI-induced neuropathic pain; EA, 2-, 15- and 50-Hz, 20 min | GV20, GV14 | Expression of the GABAA receptor and the level of glutamate in the hippocampus and periaqueductal gray (PAG) area. | EA reduced the pain response; suppressed hippocampal GABAA receptors; decreased thalamic glutamate levels. |
| Lin et al., (2002) [ | Human | Preoperative EA, 2- (low) or 100- (high) Hz, 20 min | Bilateral ST36 | Postoperative pain and opioid-related side effects | Both low- and high-frequency EA reduced postoperative analgesic requirements and associated side effects. |
| Wang et al., (1997) [ | Human | Postoperative TAES, 2- (low) or 100- (high) Hz, 30 min | Bilateral LI4 | Postoperative pain and opioid-related side effects | Both low- and high-frequency EA reduced postoperative analgesic requirements and associated side effects. |
| Chen et al. (2011) [ | CD1 mice | EA, 2-Hz, 20 min | Bilateral ST36 | Behavioral responses in the paw and ASIC3 overexpression in DRG neurons. | Rescued mechanical hyperalgesia and an ASIC3 downregulation. |
| Chen et al. (2012) [ | ICR mice | EA, 2-Hz, 15 min | Bilateral ST36 | Behavioral responses in the paw and TRPV1/4 overexpression in DRG neurons. | TRPV1 and TRPV4 upregulation in DRG neurons was attenuated by EA. |
| Huang et al. (2013) [ | ICR mice | EA, 2-Hz, 15 min | Bilateral ST36 | Behavioral responses in the paw and the overexpression of Nav1 in DRG neurons. | EA attenuated inflammatory pain by suppressing Nav1 overexpression. |
| Wu et al. (2014) [ | ICR mice | MA, 60 min | Ipsilateral ST36 of the inflamed limb | Behavioral responses in paw; the overexpression of TRPV1/4, ASIC3, and CWP components in the anatomical layers of ST36. | MA induced analgesia, with high TRPV1 and CWP overexpression at ST36 upon MA. |
| Lu et al. (2016) [ | C57/B6 mice | EA, 2-Hz, 15 min | Ipsilateral and contralateral ST36-ST37 of the inflamed limb | Behavioral responses in the paw; Nav and TRPV1 overexpression in DRG neurons. | Hyperalgesia was suppressed through ipsilateral and contralateral EA. Nav and TRPV1 were suppressed through EA. |
| Liao et al. (2017) [ | C57/B6 mice | EA, 2-Hz, 15 min | Bilateral ST36 | Behavioral responses in the paw and the expression of Nav, GFAP, Iba-1, S100B, RAGE, and TRPV1 in DRG neurons. | EA attenuated inflammatory pain by suppressing Nav1.8 through S100B, TRPV1, opioid, and adenosine pathways. |
| Liao et al. (2017) [ | C57/B6 mice | EA, 2-Hz, 15 min | Bilateral ST36 | Behavioral responses in the paw and the expression of GFAP, S100B, RAGE, PKCε, ERK, NF-κB, and COX-2 in DRG neurons. | EA attenuated inflammatory pain by suppressing opioid and adenosine pathways. |
| Yang et al. (2017) [ | C57/B6 mice | EA, 2-Hz, 15 min | Bilateral ST36 | Behavioral responses in the paw and the expression of TRPV1, PKA, PKC, PI3K, ERK1/2, p38, JNK, Akt, mTOR, CREB, NF-κB, Nav1.7/1.8, GFAP, S100B, and RAGE in DRG neurons. | EA significantly reduced chronic inflammatory pain by downregulating the TRPV1 pathway from the peripheral DRG neurons to the central spinal cord. |
| Yen et al. (2019) [ | C57/B6 mice | EA, 2-Hz, 15 min | Bilateral LI4 | Behavioral responses in the paw and the expression of TRPV1 and ERK1/2 in the prefrontal cortex, the hypothalamus, the PAG area, and DRG neurons. | Pain alleviation immediately after EA; the expression of TRPV1-associated molecules was attenuated by EA in the prefrontal cortex, the hypothalamus, the PAG area, and DRG. |
| Hsu et al. (2019) [ | C57/B6 mice | EA, 2-Hz, 15 min | Bilateral ST36 | Behavioral responses in the paw and the expression of TLR2, PI3K, ERK1/2, p38, JNK, Akt, mTOR, CREB, NF-κB, and Nav1.7/1.8 in the thalamus. | EA attenuated inflammatory pain via TLR2 signaling. |
| Yang et al. (2009) [ | Patients with CTS | MA, 30 min/session, 2 session a week, 8 session in total | Affected side(s), PC6, PC7 | Motor and sensory NCS; designed symptomatic questionnaire. | Short-term acupuncture was as effective as short-term low-dose steroid for mild-to-moderate CTS. |
| Yang et al. (2011) [ | Patients with CTS | MA, 30 min/session, 2 session a week, 8 session in total | Affected side(s), PC6, PC7 | NCS; global symptom score. | Acupuncture had superior efficacy to steroid treatment not only in terms of objective changes in nerve conduction but also in terms of subjective symptom assessment in long-term follow-up. |
| Yang et al. (2011) [ | Patients with chronic migraine (CM) | MA, 30 min/session, 2 session a week, 24 session in total | Bilateral BL2, GB20, EX-HN5, EX-HN3 (acupoints relate to the trigeminal and cervical dermatomes) | Changes in headache events, MIDAS scores, HADS scores, BDI-II scores, reduction of medication. | Acupuncture was similarly effective or more effective than prophylactic drug treatment with less side effects in migraine. |
A1R: adenosine A1 receptor; ASIC3: acid-sensing ion channel; BDI-II: Beck Depression Inventory-II; CCI: chronic constriction injury; CWP components: components of calcium wave propagation, including pannexin 1, connexin 43, P2Y1, and P2Y2, which can activate a release of ATP after mechanical stimulation of nonneural cells such as subepithelial fibroblasts; GABAA: γ-aminobutyric acid A; GFAP: glial fibrillary acidic protein, an astrocytic marker; HADS: hospital anxiety and depression scale; Iba-1: ionized calcium-binding adaptor molecule 1, a microglia/macrophage specific protein (marker); MA: manual acupuncture; MIDAS: Migraine Disability Assessment; mGluR3: metabotropic glutamate receptor 3; Navs: voltage-gated sodium channels; NCS: nerve conduction study; RAGE: receptor for advanced glycation end-products; TAES: transcutaneous acupoint electrical stimulation; 100B: calcium-binding protein B.
The p38 signaling pathway in cerebral ischemic stroke.
| Study | Model | Intervention | Acupoints | Evaluation | Result |
|---|---|---|---|---|---|
| Bäcker et al., (2003) [ | Healthy human | MA; manipulation as either high frequency (4–8 Hz) and low amplitude (Hf–La) or low frequency (1–2 Hz) and high amplitude (Lf–Ha). | Right LI4 | Cerebral blood flow velocity (CBFV) in both middle cerebral arteries, arterial blood pressure (BP), heart rate (HR). | (1) Lf–Ha stimulation was perceived as more intense and markedly increased the CBFV in the right hemisphere; (2) Hf–La stimulation slightly decreased BP and HR; (3) Lf–Ha stimulation induced an initial pressor response (increase of BP, decrease of HR) and a more marked long-term BP reduction. |
| Hsieh et al., (2006) [ | SD rats | EA, 2-Hz, 15 min | Both ST36 | The levels of nitric oxide in the peripheral blood and amounts of calcitonin gene-related peptide (CGRP) in the cerebral cortex and thalamus. L-N (G)-nitro arginine methyl ester (L-NAME) was used to measure the changes in CBF. | Both 2- and 15-Hz EA increased CBF in rats with and without CI. |
| Cheng et al. (2014) [ | SD rats | EA, 2-Hz, 25 min once daily for 2 consecutive days. | GV20, GV14 | Cerebral infarct area, caspase-3, BDNF, pRaf-1, MEK1/2, ERK1/2, p90RSK, and Bad. | EA significantly reduced the cerebral infarct area, caspase-3 protein expression levels, and apoptosis in the ischemic cortex. BDNF, phospho-Raf-1 (pRaf-1), phospho-MEK1/2 (pMEK1/2), phospho-ERK1/2 (pERK1/2), phospho-90 kDa ribosomal S6 kinase (pp90RSK), and phospho-Bad (pBad) were markedly upregulated, and neuronal nuclear antigen (NeuN) expression was restored. |
| Cheng et al. (2014) [ | SD rats | EA, 2-Hz, 15 min once daily for 6 consecutive days. | GV20, GV14 | Cerebral infarct area, GFAP, S100B, NF-κB, p50, p38 MAPK, TNF-α, and iNOS. | EA significantly reduced the cerebral infarct area and downregulated astrocytic S100B expression and decreased p-p38 NF-kB. |
| Cheng et al. (2015) [ | SD rats | EA, 5- or 25-Hz, 30 min once daily for 7 consecutive days. | GV20, GV16 | Cerebral infarct area, GFAP, Bax, Bcl-xL, Smac/DIABLO, p-p38, and CREB. | Both 5- and 25-Hz EA effectively downregulated reactive astrocytosis to exert neuroprotective effects against cerebral infarction, most likely by activating the p38 MAPK/CREB signaling pathway. |
| Xu et al. (2014) [ | SD rats | EA, 2-Hz, 20 min once a day. | GV20, ST36 | Hsp70 and TNF-α peripheral serum. | Lowered peak levels of adrenocorticotrophic hormone and Hsp70. |
| Kuo et al. (2016) [ | SD rats | Electrostimulation, 2-Hz, 20 min once daily for 7 consecutive days. | Both ears | Brain nicotinic acetylcholine receptors. | Two-hertz ES for ameliorated learning and memory impairment. |
GFAP: glial fibrillary acidic protein; iNOS: inducible nitric oxide synthase; MA: manual acupuncture; Smac/DIABLO: second mitochondrial-derived activator of caspase/direct inhibitor of apoptosis protein-binding protein with low isoelectric point.
The effect of acupuncture on epileptic seizures.
| Study | Model | Intervention | Acupoints | Evaluation | Result |
|---|---|---|---|---|---|
| Kim et al., (2008) [ | ICR mice | MA, 20 min/day, for 2 days | Bilateral HT8 | Hippocampal expression of c-Fos, c-Jun, and GAD-67 (CA1 and CA3 areas). | Reduced severity of epileptic seizures and the rate of neuronal death; downregulation of c-Fos and c-Jun; upregulation of GAD-67. |
| Kim et al. (2012) [ | C57BL/6 mice | MA, 20 min/day, for 2 days | Bilateral HT8 | Neuronal survival, microglial and astrocyte activation, and hippocampal mRNA expression of IL-1β and TNF-α. | Inhibition of hippocampal cell death and suppression of KA-induced inflammatory events. |
| Bae et al. (2013) [ | C57BL/6 mice | MA, 20 min/day, for 3 days | Bilateral HT8 | Neuronal survival and hippocampal astrocyte activation. | Acupuncture altered hippocampal protein expression to promote neuronal survival. |
| Liu et al. (2014) [ | SD rats | EA, 2 Hz, 30 min/day for 7 consecutive days. | Bilateral ST-36-ST37 and ears | Changes in mossy fibers sprouting in the hippocampus. | Amelioration of mossy fibers sprouting in the hippocampus. |
| Lin et al., (2014) [ | SD rats | EA, 2 Hz, 20 min/day, 3 days/week for 6 weeks | Bilateral ears, ST36, ST37 | EEG and EMG changes; hippocampal TRPA1, TRPV4, PKCα, PKCε, and pERK1/2 expression. | EA reduced hippocampal hyperactivity accompanied by alterations in the TRPA1, PKCε, PKCα, and pERK1/2 signaling pathways. |
| Liao et al., (2017) [ | SD rats | EA, 2 Hz, 20 min/day, 3 days/week for 6 weeks | Bilateral ears, ST36, ST37 | EEG and EMG changes; hippocampal COX-2 levels. | Attenuated COX-2 and COX-2 immunoreactive cells in the hippocampal CA1 region after epileptic seizures. |
| Liao et al. (2018) [ | SD rats | EA, 2 Hz, 20 min/day, 3 days/week for 6 weeks | Bilateral ears | Brain TLR4, CaMKIIα, ERK, JNK, and NF-κB expression. | Auricular EA controlled epileptic seizures by regulating the TLR4 signaling pathway. |
GAD-67: glutamate decarboxylase-67; c-Fos, c-Jun: proto-oncogenes that are expressed within some neurons following depolarization, the two form the AP-1 early response transcription factor that regulates gene expression in response to extracellular stimuli; KA: kainic acid; EEG: electroencephalogram; EMG: electromyogram; PKC: protein kinase C; TRPA1: transient receptor potential cation channel subfamily A member 1; TRPV: transient receptor potential vanilloid receptors; pERK: phosphor-extracellular signal-regulated kinases; COX-2: cyclooxygenase-2; TLR4: Toll-like receptor 4; CaMKIIα: calmodulin-dependent protein kinase II alpha.